Each JALRA tablet contains 50 mg of the active substance vildagliptin.


Product leaflet summary

Therapeutic Indications:

JALRA is a medicine used to treat patients with type 2 diabetes whose condition cannot be controlled by diet and exercise alone. It helps to control the level of sugar in the blood.

Such medicines are known as oral antidiabetics.


Dosage and Administration:

Your doctor will tell you exactly how many tablets of JALRA to take.

The usual dose of JALRA is 50 mg or 100 mg a day. The 50 mg dose should be taken as 50 mg once a day (morning). The 100 mg dose should be taken as 50 mg twice a day (morning and evening). Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose. Your doctor will prescribe JALRA either alone or in combination with other antidiabetic treatment depending on your condition.



Hypersensitivity to the active substance or to any of the excipients listed.


Pregnancy and Lactation:

Pregnancy category: B
There are no adequate data from the use of vildagliptin in pregnant women. Studies in animals have shown reproductive toxicity at high doses. The potential risk for humans is unknown. Due to lack of human data, JALRA should not be used during pregnancy.
It is unknown whether vildagliptin is excreted in human milk. Animal studies have shown excretion of vildagliptin in milk. JALRA should not be used during breastfeeding.


Ability to Drive and Use Machinery:

No studies on the effects of JALRA on the ability to drive and use machines have been performed. Patients who may experience dizziness as an adverse reaction should avoid driving vehicles or using machines.


Package Presentation:

  1. A box of 28 tablets each contains 50 mg vildagliptin
  2. A box of 56 tablets each contains 50 mg vildagliptin